Stay updated with breaking news from Pharma Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NeoGenomics (NASDAQ:NEO – Free Report) had its target price decreased by Benchmark from $20.00 to $18.00 in a research report released on Wednesday morning, MarketBeat Ratings reports. Benchmark currently has a buy rating on the medical research company’s stock. A number of other research analysts have also weighed in on the stock. StockNews.com initiated coverage […]
Needham & Company LLC reiterated their buy rating on shares of NeoGenomics (NASDAQ:NEO – Free Report) in a report released on Wednesday, Benzinga reports. The firm currently has a $21.00 price target on the medical research company’s stock. NEO has been the topic of a number of other research reports. BTIG Research raised shares of […]
Brown Advisory Inc. lifted its stake in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 2.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,591,204 shares of the medical research company’s stock after purchasing an additional 187,219 shares during the period. Brown […]
Brown Advisory Inc. grew its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO – Free Report) by 2.9% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,591,204 shares of the medical research company’s stock after buying an additional 187,219 shares […]
Since mid-2022, the macro acquisition environment has faced the challenges of inflation and increasing interest rates, among a variety of other headwinds.